scispace - formally typeset
Journal ArticleDOI

Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study

Reads0
Chats0
TLDR
The number of chronic myeloid leukemia (CML) patients in Germany is expected to increase further until at least 2040–2050 with a maximum of more than 20,000 CML patients as the most probable scenario.
Abstract
Purpose Due to prolonged survival, there will be many more chronic myeloid leukemia (CML) patients alive in the future. The aims of this work were to estimate the current prevalence of CML by using routine data and to project future patient numbers in Germany.

read more

Citations
More filters
Journal ArticleDOI

Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia

TL;DR: Higher out-of-pocket expense for TKI therapy is significantly associated with worse HRQoL in persons with chronic-phase CML in CCyR receiving TKI Therapy, indicating the importance of drug cost and health insurance policies on people’s HRQeL.
Journal ArticleDOI

Dasatinib dose management for the treatment of chronic myeloid leukemia.

TL;DR: Results obtained from dose optimization and discontinuation trials currently in progress will help practitioners determine the best dose and duration of dasatinib for patients with CML, because treatment decisions will be made through continued discussions between physicians and patients.
Journal ArticleDOI

Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy

TL;DR: Social-economic and clinical variables were significantly associated with PROs in persons with CML receiving TKI-therapy and better well-being, and adverse impact on daily life and work was significant associated with more interests in TKIs and less impact on subject’s dailylife and work.
Journal ArticleDOI

Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.

TL;DR: It is concluded that dasatinib, similar to nilotinib, has the adverse impact on glucose-lipid metabolism compared with imatinib.
Book ChapterDOI

Epidemiology and Etiology of Chronic Myeloid Leukemia

TL;DR: The authors ask for further research on the occurrence of secondary malignancies, other therapy-related risks, treatment of elderly patients, economic impact on healthcare systems by the expensive long-term treatment, and chances to stop treatment with TKIs in patients with complete remission without risking relapse of CML.
References
More filters
Journal ArticleDOI

Epidemiology of chronic myeloid leukaemia: an update

TL;DR: In recent population-based studies, CML patients have an overall survival that is comparable to that shown in large clinical trials, though relative survival in patients >70 years is still decreased, and the importance of socio-economic factors and health-care setting for outcome and the possible increased risk of secondary cancer in CML are areas of ongoing research.
Journal ArticleDOI

The association of active smoking with multiple cancers: national census-cancer registry cohorts with quantitative bias analysis

TL;DR: The strong association of smoking with many cancers is confirmed and the evidence for protective associations with thyroid cancer and melanoma is strengthened, and the RRs for endometrial, kidney, and esophageal cancers were slightly increased and the oropharyngeal and liver (European/other) RRs were decreased.
Journal ArticleDOI

Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort

TL;DR: Examining contemporary survival patterns in the general population of patients diagnosed with chronic myeloid leukaemia finds that population-based survival for CML is similar to that reported in clinical trials, and age loses its prognostic significance.
Related Papers (5)